FDA-cleared profile

Cleerly Labs v2.0

Cleerly, Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Web-based post-processing of cardiac CT data from CCTA performed for CAD or suspected CAD to view and analyze coronary plaques/atherosclerosis and stenosis and support measurement and visualization of coronary arteries.

Clinical role
Interactive post-processing, visualization, semi-automatic segmentation, manual editing, measurement, and CORONARY report generation to support CAD evaluation; the report is not the final physician report.
Images and patients
CT/CTA · Heart; coronary arteries, plaques, and stenosis
Key limitation
Keep in mind: The software does not replace qualified medical judgment; users must account for interpolated data that may make tissue appear healthy, and outputs are based partly on user-editable segmentation and markers. No clinical testing was conducted for this v2.0 submission; the packet relies on non-clinical testing and previously reviewed predicate results.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Web-based post-processing of cardiac CT data from CCTA performed for CAD or suspected CAD to view and analyze coronary plaques/atherosclerosis and stenosis and support measurement and visualization of coronary arteries.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart; coronary arteries, plaques, and stenosis Input: DICOM 3.0-compliant or higher cardiac CT/CCTA images from any CT scanner.
  • Who uses it?Intended users: Trained medical professionals appropriately trained in the software's functions, capabilities, and limitations.
  • What does the software produce?Output: 2D/3D coronary visualization, editable lumen and vessel-wall segmentation, plaque/stenosis/vessel measurements, annotations for stents, CTOs, dominance, and anomalies, and an interactive CORONARY report that can send its text page to PACS.
  • What is its most important limitation?Key limitation: The software does not replace qualified medical judgment; users must account for interpolated data that may make tissue appear healthy, and outputs are based partly on user-editable segmentation and markers. No clinical testing was conducted for this v2.0 submission; the packet relies on non-clinical testing and previously reviewed predicate results.

Clinical takeaway. Clinical role: Web-based post-processing of cardiac CT data from CCTA performed for CAD or suspected CAD to view and analyze coronary plaques/atherosclerosis and stenosis and support measurement and visualization of coronary arteries.

Evidence takeaway. Evidence from the reviewed source record: K202280 reports no new clinical testing; non-clinical verification and validation supported the v2.0 intended use. Predicate-comparison results reproduced Pearson correlations of 0.91 lumen volume, 0.93 vessel volume, 0.85 total plaque volume, 0.94 calcified plaque volume, 0.74 non-calcified plaque volume, and 0.53 low-density non-calcified plaque volume, with Bland-Altman agreement of 96%, 97%, 95%, 95%, 95%, and 97%, respectively. These correlation and agreement endpoints are not sensitivity, specificity, or diagnostic accuracy.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Web-based post-processing of cardiac CT data from CCTA performed for CAD or suspected CAD to view and analyze coronary plaques/atherosclerosis and stenosis and support measurement and visualization of coronary arteries.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Interactive post-processing, visualization, semi-automatic segmentation, manual editing, measurement, and CORONARY report generation to support CAD evaluation; the report is not the final physician report.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
DICOM 3.0-compliant or higher cardiac CT/CCTA images from any CT scanner.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
2D/3D coronary visualization, editable lumen and vessel-wall segmentation, plaque/stenosis/vessel measurements, annotations for stents, CTOs, dominance, and anomalies, and an interactive CORONARY report that can send its text page to PACS.
  • Exact FDA submission
  • Checked 2026-09-09
Care setting
Patients who underwent coronary computed tomography angiography (CCTA) for evaluation of CAD or suspected CAD; the FDA document does not specify a facility type.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "stenosis in patients who underwent Coronary Computed Tomography Angiography (CCTA) for evaluation of CAD or suspected CAD.". Read from the exact FDA decision document on 2026-11-14.

Intended users
Trained medical professionals appropriately trained in the software's functions, capabilities, and limitations.
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
The software does not replace qualified medical judgment; users must account for interpolated data that may make tissue appear healthy, and outputs are based partly on user-editable segmentation and markers. No clinical testing was conducted for this v2.0 submission; the packet relies on non-clinical testing and previously reviewed predicate results.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
K202280 reports no new clinical testing; non-clinical verification and validation supported the v2.0 intended use. Predicate-comparison results reproduced Pearson correlations of 0.91 lumen volume, 0.93 vessel volume, 0.85 total plaque volume, 0.94 calcified plaque volume, 0.74 non-calcified plaque volume, and 0.53 low-density non-calcified plaque volume, with Bland-Altman agreement of 96%, 97%, 95%, 95%, 95%, and 97%, respectively. These correlation and agreement endpoints are not sensitivity, specificity, or diagnostic accuracy.
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K202280 reports no new clinical testing; non-clinical verification and validation supported the v2.0 intended use. Predicate-comparison results reproduced Pearson correlations of 0.91 lumen volume, 0.93 vessel volume, 0.85 total plaque volume, 0.94 calcified plaque volume, 0.74 non-calcified plaque volume, and 0.53 low-density non-calcified plaque volume, with Bland-Altman agreement of 96%, 97%, 95%, 95%, 95%, and 97%, respectively. These correlation and agreement endpoints are not sensitivity, specificity, or diagnostic accuracy.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Cleerly Labs V2.0 regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K202280
  • IndependenceIndependence not established

K202280

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K202280. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM 3.0-compliant or higher cardiac CT/CCTA images from any CT scanner.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA K202280: Cleerly Labs v2.0

  2. Routing

    Source context, not route validation: Client-server Google Chrome application using DICOM 3.0 or higher and a secured network server; the packet describes sending the CORONARY report text page to PACS but does not establish specific PACS, RIS, EHR, hosting, or interface versions.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K202280: Cleerly Labs v2.0

  3. AI processing

    Source context, not route validation: The exact FDA package describes a post-processing web-based software application whose machine learning and calculation components are performed on the backend of the software, listed as a client-server Google Chrome application. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Cleerly Labs is a post-processing web-based software application that enables trained medical professionals to analyze 2D/3D coronary images" … "Cleerly Labs utilizes machine learning and simple rule-based mathematical calculation components which are performed on the backend of the software.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K202280: Cleerly Labs v2.0

  4. Returned objects

    Source context, not route validation: 2D/3D coronary visualization, editable lumen and vessel-wall segmentation, plaque/stenosis/vessel measurements, annotations for stents, CTOs, dominance, and anomalies, and an interactive CORONARY report that can send its text page to PACS.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA K202280: Cleerly Labs v2.0

  5. Viewer/worklist/report

    Unresolved route: 2D/3D coronary visualization, editable lumen and vessel-wall segmentation, plaque/stenosis/vessel measurements, annotations for stents, CTOs, dominance, and anomalies, and an interactive CORONARY report that can send its text page to PACS.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA K202280: Cleerly Labs v2.0

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes a post-processing web-based software application whose machine learning and calculation components are performed on the backend of the software, listed as a client-server Google Chrome application. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Cleerly Labs is a post-processing web-based software application that enables trained medical professionals to analyze 2D/3D coronary images" … "Cleerly Labs utilizes machine learning and simple rule-based mathematical calculation components which are performed on the backend of the software.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
Client-server Google Chrome application using DICOM 3.0 or higher and a secured network server; the packet describes sending the CORONARY report text page to PACS but does not establish specific PACS, RIS, EHR, hosting, or interface versions.
  • Exact FDA submission
  • Checked 2026-09-09

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Cleerly Labs v2.0; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K202280
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Heart; coronary arteries, plaques, and stenosis
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2020-10-02
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
9Source classes checked
0Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 0 PubMed and 1 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 0 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K202280 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-09 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K202280: Cleerly Labs v2.0

    U.S. Food and Drug Administration - Published 2020-10-02 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Cleerly Labs V2.0 model card (K202280)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: intendedUsers, output, limitations, evidenceSummary, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K202280

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

Research history

  1. K202280 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251027

cvi42 Coronary Plaque Software Application

Circle Cardiovascular Imaging, Inc.

Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-10-27
FDA-cleared K243229

Bunkerhill AVC

BunkerHill Health

Authorized purpose: Adjunctive opportunistic detection and quantification of aortic valve calcification during routine clinical-care chest CT review; a physician reviews the informational ROI and estimated calcium burden and decides any further action.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-01-27
FDA-cleared K183012

vascuCAP

Elucid Bioimaging Inc.

Authorized purpose: vascuCAP analyzes contrast multidetector CT of arterial vessels to support atherosclerosis stratification with color maps, three-dimensional views, multiplanar reformats, and measurements for physician review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2018-12-21

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history